What is Oculis Holding AG (OCS)?

Oculis Holding AG (OCS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of OCS?

The current price of OCS is $7.98. Prices are updated in real time on Stocks360.

What is OCS's price-to-earnings (PE) ratio?

OCS's trailing twelve-month PE ratio is -4.73, based on current price and earnings per share data available on Stocks360.

What is OCS's market capitalization?

OCS's market capitalization is $491,472,823.00, placing it in the small-cap tier.

Oculis Holding AG (OCS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$7.98

Market Cap

$491.47M

PE (TTM)

-4.73

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.23

Day Range

$7.72 – $8.05

52-wk Range

$7.11 – $34.48

Avg Volume

N/A

Volume

220.00K

Oculis Holding AG (OCS) is a publicly traded company in the Healthcare sector. Latest price: $7.98. Market cap $491.47M. Trailing PE -4.73. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $21.55 2026-10-28 · $7.98 (-62.97%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.20 vs est. $-0.48

Beat by $0.28

Next Earnings

Nov 3, 2026

EPS estimate $-0.49

Proprietary Signals

Signal snapshot temporarily unavailable.

About Oculis Holding AG

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.73×
P/S (TTM)	1676.75×
P/B	1.85×
P/FCF (TTM)	-6.17×
EV / EBITDA	-5.23×
EV / Sales	1687.18×
Earnings Yield	-19.65%
Free Cash Flow Yield	-16.21%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$409.99M
Revenue (TTM)	$243.00K
Net Income (TTM)	-$80.07M
Free Cash Flow (TTM)	-$65.13M
Net Debt	$2.54M
Working Capital	$205.14M
Gross Margin	35.21%
Operating Margin	-35874.24%
Net Margin	-32780.20%
Return on Equity	-42.92%
Return on Invested Capital	-38.94%